Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib in Chinese patients with advanced cancer
NCT02919696Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of abemaciclib in cancer and metastatic cancer (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Drug Related Adverse Events. Started Aug 2017; status: completed.
02
Drugs
abemaciclib
03
Conditions
cancermetastatic cancer
Beyond the preview
Go deeper on NCT02919696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02919696.